JP5279209B2 - Topical skin preparation - Google Patents
Topical skin preparation Download PDFInfo
- Publication number
- JP5279209B2 JP5279209B2 JP2007167688A JP2007167688A JP5279209B2 JP 5279209 B2 JP5279209 B2 JP 5279209B2 JP 2007167688 A JP2007167688 A JP 2007167688A JP 2007167688 A JP2007167688 A JP 2007167688A JP 5279209 B2 JP5279209 B2 JP 5279209B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- acid
- weight
- tocopherol
- external preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 230000000699 topical effect Effects 0.000 title description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 87
- 239000004202 carbamide Substances 0.000 claims abstract description 45
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 26
- 229930003799 tocopherol Natural products 0.000 claims description 24
- 239000011732 tocopherol Substances 0.000 claims description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 23
- 235000010384 tocopherol Nutrition 0.000 claims description 23
- 229960001295 tocopherol Drugs 0.000 claims description 23
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229960001727 tretinoin Drugs 0.000 claims description 10
- 229930002330 retinoic acid Natural products 0.000 claims description 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 6
- 229940108325 retinyl palmitate Drugs 0.000 claims description 6
- 239000011769 retinyl palmitate Substances 0.000 claims description 6
- 229940042585 tocopherol acetate Drugs 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 229960000342 retinol acetate Drugs 0.000 claims description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 4
- 235000019173 retinyl acetate Nutrition 0.000 claims description 4
- 239000011770 retinyl acetate Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 229940012831 stearyl alcohol Drugs 0.000 claims description 3
- 150000003611 tocopherol derivatives Chemical class 0.000 claims description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 2
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 2
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims description 2
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 2
- 229950009883 tocopheryl nicotinate Drugs 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 claims 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- 229960004488 linolenic acid Drugs 0.000 claims 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract description 68
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 35
- 229960003471 retinol Drugs 0.000 abstract description 34
- 235000020944 retinol Nutrition 0.000 abstract description 34
- 239000011607 retinol Substances 0.000 abstract description 34
- 230000003020 moisturizing effect Effects 0.000 abstract description 8
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- -1 retinol fatty acid ester Chemical class 0.000 description 43
- 230000000694 effects Effects 0.000 description 26
- 238000012360 testing method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 229920001577 copolymer Polymers 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 108010076876 Keratins Proteins 0.000 description 7
- 102000011782 Keratins Human genes 0.000 description 7
- 239000004359 castor oil Substances 0.000 description 7
- 235000019438 castor oil Nutrition 0.000 description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 230000001153 anti-wrinkle effect Effects 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229940083542 sodium Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 229940014041 hyaluronate Drugs 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960002684 aminocaproic acid Drugs 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 235000019161 pantothenic acid Nutrition 0.000 description 3
- 239000000467 phytic acid Substances 0.000 description 3
- 235000002949 phytic acid Nutrition 0.000 description 3
- 229940068041 phytic acid Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 229940092258 rosemary extract Drugs 0.000 description 3
- 235000020748 rosemary extract Nutrition 0.000 description 3
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- 235000020955 thiamine monophosphate Nutrition 0.000 description 3
- 239000011621 thiamine monophosphate Substances 0.000 description 3
- IWLROWZYZPNOFC-UHFFFAOYSA-O thiamine triphosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N IWLROWZYZPNOFC-UHFFFAOYSA-O 0.000 description 3
- GUGWNSHJDUEHNJ-UHFFFAOYSA-N thiamine(1+) monophosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N GUGWNSHJDUEHNJ-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- LEJBBGNFPAFPKQ-UHFFFAOYSA-N 2-(2-prop-2-enoyloxyethoxy)ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCCOC(=O)C=C LEJBBGNFPAFPKQ-UHFFFAOYSA-N 0.000 description 2
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229940069521 aloe extract Drugs 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000010389 delta-tocopherol Nutrition 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229960002350 guaiazulen Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 2
- 229960001669 kinetin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 229940040452 linolenate Drugs 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 150000002948 pantothenic acids Chemical class 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 2
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 2
- 239000011678 thiamine pyrophosphate Substances 0.000 description 2
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- 239000002446 δ-tocopherol Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MXFQRSUWYYSPOC-UHFFFAOYSA-N (2,2-dimethyl-3-prop-2-enoyloxypropyl) prop-2-enoate Chemical compound C=CC(=O)OCC(C)(C)COC(=O)C=C MXFQRSUWYYSPOC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- DAFHKNAQFPVRKR-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylpropanoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)C DAFHKNAQFPVRKR-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QWOZZTWBWQMEPD-UHFFFAOYSA-N 1-(2-ethoxypropoxy)propan-2-ol Chemical compound CCOC(C)COCC(C)O QWOZZTWBWQMEPD-UHFFFAOYSA-N 0.000 description 1
- TXECTBGVEUDNSL-UHFFFAOYSA-N 1-acetyloxyprop-2-enyl acetate Chemical compound CC(=O)OC(C=C)OC(C)=O TXECTBGVEUDNSL-UHFFFAOYSA-N 0.000 description 1
- YAYNEUUHHLGGAH-UHFFFAOYSA-N 1-chlorododecane Chemical compound CCCCCCCCCCCCCl YAYNEUUHHLGGAH-UHFFFAOYSA-N 0.000 description 1
- CLWAXFZCVYJLLM-UHFFFAOYSA-N 1-chlorohexadecane Chemical compound CCCCCCCCCCCCCCCCCl CLWAXFZCVYJLLM-UHFFFAOYSA-N 0.000 description 1
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- DJCYDDALXPHSHR-UHFFFAOYSA-N 2-(2-propoxyethoxy)ethanol Chemical compound CCCOCCOCCO DJCYDDALXPHSHR-UHFFFAOYSA-N 0.000 description 1
- XYVAYAJYLWYJJN-UHFFFAOYSA-N 2-(2-propoxypropoxy)propan-1-ol Chemical compound CCCOC(C)COC(C)CO XYVAYAJYLWYJJN-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- OVOUKWFJRHALDD-UHFFFAOYSA-N 2-[2-(2-acetyloxyethoxy)ethoxy]ethyl acetate Chemical compound CC(=O)OCCOCCOCCOC(C)=O OVOUKWFJRHALDD-UHFFFAOYSA-N 0.000 description 1
- ZLBRIKBFTAESRO-UHFFFAOYSA-N 2-[2-(2-pentanoyloxyethoxy)ethoxy]ethyl pentanoate Chemical compound CCCCC(=O)OCCOCCOCCOC(=O)CCCC ZLBRIKBFTAESRO-UHFFFAOYSA-N 0.000 description 1
- ZYVAQZSGKALVEU-UHFFFAOYSA-N 2-[2-[bis(2-hydroxy-2-oxoethyl)amino]ethyl-(2-hydroxy-2-oxoethyl)amino]ethanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O ZYVAQZSGKALVEU-UHFFFAOYSA-N 0.000 description 1
- UHDPBLMLEMNPKP-UHFFFAOYSA-M 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol thiocyanate Chemical compound [S-]C#N.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UHDPBLMLEMNPKP-UHFFFAOYSA-M 0.000 description 1
- WTPYFJNYAMXZJG-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)phenoxy]ethanol Chemical compound OCCOC1=CC=C(OCCO)C=C1 WTPYFJNYAMXZJG-UHFFFAOYSA-N 0.000 description 1
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- HXDLWJWIAHWIKI-UHFFFAOYSA-N 2-hydroxyethyl acetate Chemical compound CC(=O)OCCO HXDLWJWIAHWIKI-UHFFFAOYSA-N 0.000 description 1
- GWZMWHWAWHPNHN-UHFFFAOYSA-N 2-hydroxypropyl prop-2-enoate Chemical compound CC(O)COC(=O)C=C GWZMWHWAWHPNHN-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FQMIAEWUVYWVNB-UHFFFAOYSA-N 3-prop-2-enoyloxybutyl prop-2-enoate Chemical compound C=CC(=O)OC(C)CCOC(=O)C=C FQMIAEWUVYWVNB-UHFFFAOYSA-N 0.000 description 1
- LDMRLRNXHLPZJN-UHFFFAOYSA-N 3-propoxypropan-1-ol Chemical compound CCCOCCCO LDMRLRNXHLPZJN-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ZMFWEWMHABZQNB-UHFFFAOYSA-N 6-acetyloxyhexyl acetate Chemical compound CC(=O)OCCCCCCOC(C)=O ZMFWEWMHABZQNB-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 241000544061 Cuculus canorus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AZJUFRDUYTYIHV-NKFKGCMQSA-N Dibenzoyl Thiamine Chemical compound C=1C=CC=CC=1C(=O)OCC\C(SC(=O)C=1C=CC=CC=1)=C(/C)N(C=O)CC1=CN=C(C)N=C1N AZJUFRDUYTYIHV-NKFKGCMQSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- QEKBRBCVWVLFHH-QAKUKHITSA-L Tocopherol calcium succinate Chemical compound [Ca+2].[O-]C(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C.[O-]C(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C QEKBRBCVWVLFHH-QAKUKHITSA-L 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 1
- TXGSMRRWACWHFZ-MVIDNBQJSA-N [(2r,3s,4s)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-tris(pyridine-3-carbonyloxy)pentyl] pyridine-3-carboxylate Chemical compound O([C@@H](CN1C=2C(C(NC(=O)N=2)=O)=NC=2C=C(C(=CC=21)C)C)[C@H](OC(=O)C=1C=NC=CC=1)[C@@H](COC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 TXGSMRRWACWHFZ-MVIDNBQJSA-N 0.000 description 1
- DDEDPQYNISJXLF-XTMYEIJHSA-N [(z)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-benzoylsulfanylpent-3-enyl] benzoate;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(=O)OCC\C(SC(=O)C=1C=CC=CC=1)=C(/C)N(C=O)CC1=CN=C(C)N=C1N DDEDPQYNISJXLF-XTMYEIJHSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- ZGISOPBIAXHOTQ-OUGXGHBNSA-N all-trans-retinyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C ZGISOPBIAXHOTQ-OUGXGHBNSA-N 0.000 description 1
- XJKITIOIYQCXQR-SCUNHAKFSA-N all-trans-retinyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XJKITIOIYQCXQR-SCUNHAKFSA-N 0.000 description 1
- FXKDHZXYYBPLHI-TUTABMRPSA-N all-trans-retinyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FXKDHZXYYBPLHI-TUTABMRPSA-N 0.000 description 1
- YNGACJMSLZMZOX-FPFNAQAWSA-N all-trans-retinyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C YNGACJMSLZMZOX-FPFNAQAWSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- RNSLCHIAOHUARI-UHFFFAOYSA-N butane-1,4-diol;hexanedioic acid Chemical compound OCCCCO.OC(=O)CCCCC(O)=O RNSLCHIAOHUARI-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- LYAGTVMJGHTIDH-UHFFFAOYSA-N diethylene glycol dinitrate Chemical compound [O-][N+](=O)OCCOCCO[N+]([O-])=O LYAGTVMJGHTIDH-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- PSXCGTLGGVDWFU-UHFFFAOYSA-N propylene glycol dinitrate Chemical compound [O-][N+](=O)OC(C)CO[N+]([O-])=O PSXCGTLGGVDWFU-UHFFFAOYSA-N 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- PFIPZKASKUWLHH-UHFFFAOYSA-N pyridoxamine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CN)=C1O PFIPZKASKUWLHH-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- AGCQZYRSTIRJFM-UHFFFAOYSA-N triethylene glycol dinitrate Chemical compound [O-][N+](=O)OCCOCCOCCO[N+]([O-])=O AGCQZYRSTIRJFM-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、尿素とレチノールまたはその誘導体を含有する使用感に優れた皮膚外用剤に
関する。さらに本発明は、保湿性、製剤安定性、安全性に優れた皮膚外用剤に関する。
The present invention relates to a skin external preparation excellent in feeling of use containing urea and retinol or a derivative thereof. Furthermore, this invention relates to the skin external preparation excellent in moisture retention, formulation stability, and safety.
尿素は、保湿剤、浸透補助剤、荒れ肌改善剤、皮膚軟化剤、細胞賦活剤等として外用組
成物に広く用いられている成分である。しかし、高い保湿力や皮膚軟化力を与えるために
尿素を高濃度配合した組成物は、尿素が析出しやすいため尿素本来の薬理作用および塗布
時の使用感を損ねてしまうことが問題となる。このため、尿素の析出を抑制するための検
討が古くからなされており、例えば、尿素を0.5〜30重量%、多価アルコールを25〜80重量
%、水を20〜70重量%、他2成分を含有する透明ゲル製剤において、尿素が30重量%以上に
なると結晶析出の問題が生じるとの記載があり(特許文献1:特開昭63-166825号公報)
、尿素が30重量%以下であれば析出を防止できることが示唆されている。
一方、レチノールまたはその誘導体は、視覚、聴覚などの生体機能の維持や、新陳代謝
を促進することによる皮膚や粘膜などの正常な上皮組織の再生機能などに関与することが
知られたビタミンであり、角化性皮膚疾患(尋常性魚鱗癬、毛孔性苔癬、単純性粃糠疹等
)などの外用医薬品として、また抗酸化作用、老化防止作用などから、抗しわ等の皮膚老
化防止用の化粧料などとして、広く利用されている。しかし、高濃度の尿素と組み合わせ
ることによる効果については知られていない。
さらに、尿素は皮膚に対して刺激を与える場合や、加水分解を受けてアンモニア臭を生
じる場合があることから、安全性および製剤安定性を改善することも望まれている。
Urea is a component widely used in external compositions as a moisturizer, penetration aid, rough skin improving agent, emollient, cell activator, and the like. However, a composition containing urea at a high concentration in order to give high moisturizing power and emollient power is problematic in that urea tends to precipitate and impairs the original pharmacological action of urea and the feeling during use. For this reason, studies have been made for a long time to suppress urea precipitation. For example, urea is 0.5 to 30% by weight and polyhydric alcohol is 25 to 80% by weight.
In a transparent gel preparation containing 20% by weight, 20 to 70% by weight of water, and other two components, there is a description that a problem of crystal precipitation occurs when urea becomes 30% by weight or more (Patent Document 1: Japanese Patent Laid-Open No. 63-63). No. 166825)
It is suggested that precipitation can be prevented if urea is 30% by weight or less.
On the other hand, retinol or its derivative is a vitamin known to be involved in the maintenance of biological functions such as vision and hearing, and the regeneration function of normal epithelial tissues such as skin and mucous membranes by promoting metabolism, Cosmetics for the prevention of skin aging such as anti-wrinkles as a topical medicine for keratinized skin diseases (such as ichthyosis vulgaris, pore lichen, simple rash) Widely used as a fee. However, the effect of combining with a high concentration of urea is not known.
Furthermore, since urea may irritate the skin or it may undergo hydrolysis to produce an ammonia odor, it is also desired to improve safety and formulation stability.
本発明は、高濃度の尿素を含有し、使用感に優れた皮膚外用剤を提供することを課題と
する。さらに本発明は、保湿性、製剤安定性、安全性に優れた皮膚外用剤を提供すること
を課題とする。
This invention makes it a subject to provide the skin external preparation excellent in the usability | use_condition containing high concentration urea. Furthermore, this invention makes it a subject to provide the skin external preparation excellent in moisture retention, formulation stability, and safety | security.
本発明者らは、上記の目的を達成すべく鋭意研究を行った結果、高濃度の尿素を含有す
る組成物に、レチノールまたはその誘導体を加えると、使用感が向上することを見出した
。また、保湿性、製剤安定性、安全性にも優れることを見出し、本発明を完成した。
すなわち本発明は、下記(1)〜(5)に掲げる皮膚外用剤である。
(1)尿素10〜25重量%およびレチノールまたはその誘導体を含有する皮膚外用剤。
(2)レチノール誘導体が、レチノール脂肪酸エステル、レチノール酸化物およびレチノ
ール酸化物エステルからなる群から選択される(1)に記載の皮膚外用剤。
(3)レチノール誘導体が、酢酸レチノール、パルミチン酸レチノール、δ-レチノイン
酸トコフェロールからなる群から選択される1種又は2種以上である(1)に記載の皮膚
外用剤。
(4)さらにトコフェロールまたはその誘導体を含有する(1)〜(3)のいずれかに記
載の皮膚外用剤。
(5)さらに、キレート剤、抗酸化剤、抗炎症剤、保湿剤、美白剤、細胞賦活化剤および
抗シワ剤を含有する(1)〜(4)のいずれかに記載の皮膚外用剤。
また、本発明は以下の方法をも包含する。
(6)尿素および、レチノールまたはその誘導体を含有することによる、尿素析出抑制方法
。
(7)さらにトコフェロールまたはその誘導体を含有する(6)記載の方法。
(8)尿素および、レチノールまたはその誘導体を含有することによる、レチノールまたはその誘導体の安定化方法。
As a result of intensive studies to achieve the above object, the present inventors have found that the use feeling is improved when retinol or a derivative thereof is added to a composition containing a high concentration of urea. In addition, the inventors have found that it is excellent in moisture retention, formulation stability and safety, and completed the present invention.
That is, this invention is a skin external preparation listed to following (1)-(5).
(1) A skin external preparation containing 10 to 25% by weight of urea and retinol or a derivative thereof.
(2) The skin external preparation according to (1), wherein the retinol derivative is selected from the group consisting of a retinol fatty acid ester, a retinol oxide, and a retinol oxide ester.
(3) The skin external preparation according to (1), wherein the retinol derivative is one or more selected from the group consisting of retinol acetate, retinol palmitate, and δ-retinoic acid tocopherol.
(4) The external preparation for skin according to any one of (1) to (3), further containing tocopherol or a derivative thereof.
(5) The skin external preparation according to any one of (1) to (4), further comprising a chelating agent, an antioxidant, an anti-inflammatory agent, a moisturizing agent, a whitening agent, a cell activator and an anti-wrinkle agent.
The present invention also includes the following methods.
(6) A method for suppressing urea precipitation by containing urea and retinol or a derivative thereof.
(7) The method according to (6), further comprising tocopherol or a derivative thereof.
(8) A method for stabilizing retinol or a derivative thereof by containing urea and retinol or a derivative thereof.
本発明は、高濃度の尿素とレチノールまたはその誘導体を含有することで、使用感に優
れた皮膚外用剤を提供することができる。さらに本発明は、高濃度の尿素とレチノールま
たはその誘導体を含有することで、保湿性を向上することができる。
This invention can provide the skin external preparation excellent in the usability | use_condition by containing a high concentration urea and retinol or its derivative (s). Furthermore, this invention can improve moisture retention by containing a high concentration urea and retinol or its derivative (s).
本発明の皮膚外用剤は、尿素10〜25重量%およびレチノールまたはその誘導体を含有す
ることを特徴とする。
The external preparation for skin of the present invention is characterized by containing 10 to 25% by weight of urea and retinol or a derivative thereof.
本発明で用いる尿素の配合量は、本発明の効果を奏すれば特に制限されないが、皮膚外
用剤全体として、10〜25重量%、好ましくは10〜20重量%、特に好ましくは15〜20重量%
であれば良い。
The amount of urea used in the present invention is not particularly limited as long as the effects of the present invention are exhibited, but as a whole external preparation for skin, 10 to 25% by weight, preferably 10 to 20% by weight, particularly preferably 15 to 20% by weight. %
If it is good.
本発明においてレチノール誘導体とは、酢酸レチノール、プロピオン酸レチノール、酪
酸レチノール、オクチル酸レチノール、ラウリル酸レチノール、パルミチン酸レチノール
、ステアリン酸レチノール、ミリスチン酸レチノール、オレイン酸レチノール、リノレン
酸レチノール、リノール酸レチノールなどのレチノール脂肪酸エステル、レチナール、レ
チノイン酸などのレチノール酸化物、レチノイン酸メチル、レチノイン酸エチル、レチノ
イン酸レチノール、レチノイン酸トコフェロール(トコフェロールは、α、β、γ、δのいずれの構造であってもよい。)などのレチノイン酸エステルなどが挙げられ、レチノイン酸においては塩であってもよい(例えば、レチノイン酸ナトリウムなど)。好ましくは酢酸レチノール、パルミチン酸レチノール、δ-レチノイン酸トコフェロールである。
In the present invention, retinol derivatives include retinol acetate, retinol propionate, retinol butyrate, retinol octylate, retinol laurate, retinol palmitate, retinol stearate, retinol myristate, retinol oleate, retinol linolenate, retinol linoleate, etc. Retinol fatty acid esters, retinal, retinoic acid such as retinoic acid, methyl retinoic acid, ethyl retinoic acid, retinol retinoic acid, tocopherol retinoic acid (tocopherol may have any structure of α, β, γ, δ ) And the like, and retinoic acid may be a salt (for example, sodium retinoic acid). Preferred are retinol acetate, retinol palmitate, and tocopherol δ-retinoate.
また本発明に用いるレチノールまたはその誘導体は、動物から抽出、精製した天然油(
肝油など)であっても、化学合成したものであっても良い。また、日本薬局方記載のビタ
ミンA油(1gにつき3万ビタミンA単位(IU)以上を含む)であってもよい。
In addition, retinol or a derivative thereof used in the present invention is a natural oil extracted and purified from animals (
Liver oil, etc.) or chemically synthesized. It may also be a vitamin A oil described in the Japanese Pharmacopoeia (including 30,000 vitamin A units (IU) or more per gram).
本発明で用いるレチノールまたはその誘導体の配合量は、本発明の効果を奏すれば特に
制限されないが、皮膚外用剤全体として、0.001〜1重量%、好ましくは0.01〜0.5重量%
であれば良い。
The amount of retinol or a derivative thereof used in the present invention is not particularly limited as long as the effect of the present invention is achieved, but as a whole external preparation for skin, 0.001 to 1% by weight, preferably 0.01 to 0.5% by weight.
If it is good.
また、本発明の皮膚外用剤において、レチノールまたはその誘導体に対する尿素の割合
は、本発明の効果を奏すれば特に制限されないが、レチノールまたはその誘導体の総量1
重量部に対して、尿素が通常1〜300重量部、好ましくは10〜200重量部、特に好ましくは2
0〜100重量部である。
Further, in the external preparation for skin of the present invention, the ratio of urea to retinol or a derivative thereof is not particularly limited as long as the effect of the present invention is exerted, but the total amount of retinol or a derivative thereof is 1
Urea is usually 1 to 300 parts by weight, preferably 10 to 200 parts by weight, particularly preferably 2 parts by weight.
0 to 100 parts by weight.
本発明の皮膚外用剤には、使用感、保湿性をさらに向上させるため、また製剤を安定化
させるために、トコフェロールまたはその誘導体を配合することができる。
本発明においてトコフェロールとは、α−トコフェロール、β−トコフェロール、γ−
トコフェロール、δ−トコフェロールのいずれでもよく、好ましくはα−トコフェロール
、δ−トコフェロールである。これらのトコフェロールは、d体、dl体のいずれであっ
てもよい。
また、トコフェロール誘導体とは、酢酸トコフェロール、コハク酸トコフェロール、ニ
コチン酸トコフェロール、リノレン酸トコフェロールなどのトコフェロール有機酸エステ
ルが挙げられ、有機酸がモノカルボン酸ではない場合は塩であってもよく(例えば、コハ
ク酸トコフェロールカルシウムなど)、好ましくは酢酸トコフェロールである。
これらのトコフェロール誘導体においても、d体、dl体のいずれであってもよい。
To the skin external preparation of the present invention, tocopherol or a derivative thereof can be blended in order to further improve the feeling of use and moisture retention and to stabilize the preparation.
In the present invention, tocopherol means α-tocopherol, β-tocopherol, γ-
Either tocopherol or δ-tocopherol may be used, and α-tocopherol and δ-tocopherol are preferred. These tocopherols may be either d-form or dl-form.
In addition, the tocopherol derivative includes tocopherol organic acid esters such as tocopherol acetate, tocopherol succinate, tocopherol nicotinate and tocopherol linolenate, and may be a salt when the organic acid is not a monocarboxylic acid (for example, Tocopherol calcium succinate), preferably tocopherol acetate.
These tocopherol derivatives may be either d-form or dl-form.
本発明で用いるトコフェロールまたはその誘導体の配合量は、本発明の効果を奏すれば
特に制限されないが、皮膚外用剤全体として、0.001〜5重量%、好ましくは0.01〜3重量
%、特に好ましくは0.5〜2重量%であれば良い。
The blending amount of tocopherol or a derivative thereof used in the present invention is not particularly limited as long as the effects of the present invention are obtained, but 0.001 to 5% by weight, preferably 0.01 to 3% by weight, particularly preferably 0.5% as a whole for the external preparation for skin. It should be ~ 2% by weight.
本発明の皮膚外用剤には、製剤安定化のため、キレート剤または抗酸化剤を1種または
2種以上組み合わせて配合することができる。これらの各成分としては、医薬品、医薬部
外品、または化粧品分野において皮膚外用剤の成分として従来から使用され、また将来使
用されるものであれば特に制限されず、任意のものを適宜選択し使用することができる。
The external preparation for skin of the present invention can be blended with one or more chelating agents or antioxidants in order to stabilize the preparation. Each of these components is not particularly limited as long as it is conventionally used as a component of a skin external preparation in the pharmaceutical, quasi-drug, or cosmetic field, and used in the future. Can be used.
キレート剤としては、例えば、エチレンジアミン4酢酸(エデト酸)、エチレンジアミ
ン4酢酸塩(ナトリウム塩(エデト酸ナトリウム:日本薬局方、EDTA−2Naなど)
、カリウム塩など)、フィチン酸、グルコン酸、ポリリン酸、メタリン酸などが挙げられ
、好ましくは、エデト酸、エデト酸ナトリウム、エデト酸カリウム、フィチン酸である。
Examples of the chelating agent include ethylenediaminetetraacetic acid (edetic acid), ethylenediaminetetraacetic acid salt (sodium salt (sodium edetate: Japanese Pharmacopoeia, EDTA-2Na, etc.)
, Potassium salts, etc.), phytic acid, gluconic acid, polyphosphoric acid, metaphosphoric acid, and the like. Preferred are edetic acid, sodium edetate, potassium edetate, and phytic acid.
これらのキレート剤は1種又は2種以上を組み合わせて使用でき、本発明の皮膚外用剤
に配合する割合は、キレート剤の合計量として、皮膚外用剤全体に対して通常0.0003〜20
重量%であり、好ましくは0.01〜10重量%、特に好ましくは0.05〜5重量%であれば良い
。
These chelating agents can be used singly or in combination of two or more. The proportion of the chelating agent blended in the external preparation for skin of the present invention is usually 0.0003 to 20 for the entire external preparation for skin as the total amount of the chelating agent.
% By weight, preferably 0.01 to 10% by weight, particularly preferably 0.05 to 5% by weight.
抗酸化剤としては、ブチルヒドロキシアニソール、ジブチルヒドロキシトルエン、亜硫
酸水素ナトリウム、エリソルビン酸及びその塩、グルタチオン、グルタチオンペルオキシ
ダーゼ、グルタチオン-S-トランスフェラーゼ、カタラーゼ、スーパーオキサイドジスム
ターゼ、チオレドキシン、タウリン、チオタウリン、ヒポタウリンなどが挙げられる。好
ましくは、ブチルヒドロキシアニソール、ジブチルヒドロキシトルエンである。
Antioxidants include butylhydroxyanisole, dibutylhydroxytoluene, sodium bisulfite, erythorbic acid and its salts, glutathione, glutathione peroxidase, glutathione-S-transferase, catalase, superoxide dismutase, thioredoxin, taurine, thiotaurine, hypotaurine, etc. Can be mentioned. Preferred are butylhydroxyanisole and dibutylhydroxytoluene.
抗酸化成分を用いる場合、本発明の効果を奏すれば特に制限されず、皮膚への使用感や
効果を考慮して適宜選択して用いることができるが、皮膚外用剤全体に対して、通常0.00
001〜10重量%、好ましくは0.0001〜5重量%、より好ましくは0.001〜5重量%である。
When an antioxidant component is used, it is not particularly limited as long as the effects of the present invention are exhibited, and can be appropriately selected and used in consideration of the feeling of use and effects on the skin. 0.00
It is 001-10 weight%, Preferably it is 0.0001-5 weight%, More preferably, it is 0.001-5 weight%.
本発明の皮膚外用剤には、他の有用な作用を付加するため、抗炎症剤、保湿剤、美白剤
、細胞賦活化剤、抗シワ剤等の各種成分を1種または2種以上組み合わせて配合すること
ができる。好ましくは抗炎症剤または細胞賦活剤の1種または2種以上の成分である。こ
れらの各成分としては、医薬品、医薬部外品、または化粧品分野において皮膚外用剤の成
分として従来から使用され、また将来使用されるものであれば特に制限されず、任意のも
のを適宜選択し使用することができる。
In order to add other useful effects to the external preparation for skin of the present invention, various components such as an anti-inflammatory agent, a moisturizing agent, a whitening agent, a cell activator, an anti-wrinkle agent, etc. are used alone or in combination. Can be blended. Preferably, it is one or more components of an anti-inflammatory agent or a cell activator. Each of these components is not particularly limited as long as it is conventionally used as a component of a skin external preparation in the pharmaceutical, quasi-drug, or cosmetic field, and used in the future. Can be used.
抗炎症剤としては、インドメタシン、サリチル酸メチル、アラントイン、アラントイン
β−グリチルレチン、アラントインクロルヒドロキシルアルミニウム、グリチルリチン酸
、グリチルリチン酸ジカリウム、グリチルリチン酸モノアンモニウム、グリチルレチン酸
、グリチルレチン酸ステアリル、グリチルレチン酸ピリドキシン、酸化亜鉛、アズレンス
ルホン酸、グアイアズレンスルホン酸、塩酸ピリドキシン、塩化リゾチーム、メントール
、カンフル等が挙げられる。好ましくは、アラントイン、グリチルリチン酸ジカリウム、
グリチルリチン酸モノアンモニウム、グアイアズレンスルホン酸、メントールである。
Anti-inflammatory agents include indomethacin, methyl salicylate, allantoin, allantoin β-glycyrrhetin, allantochlorohydroxyaluminum, glycyrrhizic acid, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, glycyrrhetinic acid, stearyl glycyrrhetinate, pyridoxine glycyrrhetinate, zinc oxide, azulene Examples include sulfonic acid, guaiazulene sulfonic acid, pyridoxine hydrochloride, lysozyme chloride, menthol, camphor and the like. Preferably, allantoin, dipotassium glycyrrhizinate,
Monoammonium glycyrrhizinate, guaiazulene sulfonic acid, and menthol.
上記抗炎症剤を用いる場合、本発明の皮膚外用剤に配合する割合は、本発明の効果を奏
すれば特に制限されず、皮膚への使用感や効果を考慮して適宜選択して用いることができ
るが、皮膚外用剤全体に対して、通常0.0003〜10重量%であり、好ましくは0.01〜5重量
%である。
When the anti-inflammatory agent is used, the ratio to be blended in the external preparation for skin of the present invention is not particularly limited as long as the effects of the present invention are exhibited, and should be appropriately selected and used in consideration of use feeling and effects on the skin. However, it is usually 0.0003 to 10% by weight, preferably 0.01 to 5% by weight, based on the whole external preparation for skin.
保湿剤としては、アラニン、セリン、ロイシン、イソロイシン、スレオニン、グリシン
、プロリン、ヒドロキシプロリン、アスパラギン酸、アルギニン、テアニンなどのアミノ
酸及びその誘導体;エチレングリコール、プロピレングリコール、1,3−ブチレングリコ
ール、グリセリン、ジエチレングリコール、トリエチレングリコール、テトラエチレング
リコール、ジプロピレングリコール、ジグリセリン、ポリエチレングリコールなどの多価
アルコール;エチレングリコールモノメチルエーテル、エチレングリコールモノエチルエ
ーテル、エチレングリコールモノプロピルエーテル、ジエチレングリコールモノメチルエ
ーテル、ジエチレングリコールモノエチルエーテル、ジエチレングリコールモノプロピル
エーテル、ジエチレングリコールモノブチルエーテル、プロピレングリコールモノエチル
エーテル、プロピレングリコールモノプロピルエーテル、ジプロピレングリコールモノエ
チルエーテル、ジプロピレングリコールモノプロピルエーテルなどのグリコールエーテル
;マンニトール、ソルビトール、エリスリトール、キシリトール、トレハロースなどの糖
アルコール;レシチン、水素添加レシチン等のリン脂質;ヒアルロン酸ナトリウム、アセ
チルヒアルロン酸ナトリウム、ヘパリン類似物質、コンドロイチン硫酸ナトリウム等のム
コ多糖;コラーゲン、エラスチン、ケラチン、キチン、キトサン、ゼラチン、ポリグルタ
ミン酸などの高分子化合物;乳酸ナトリウム、ピロリドンカルボン酸ナトリウムなどのN
MF由来成分;カミツレエキス、アロエエキス、アロエベラエキス、ハマメリスエキス、
ローズマリーエキス、タイムエキス、チャエキス、シソエキスなどの植物抽出エキスのほ
か、などが挙げられる。好ましくは、グリシン、グリセリン、1,3-ブチレングリコール、
ジプロピレングリコール、ジグリセリン、ジエチレングリコールモノエチルエーテル、ヒ
アルロン酸ナトリウム、アセチルヒアルロン酸ナトリウム、ピロリドンカルボン酸ナトリ
ウム、ポリグルタミン酸である。
As the humectant, amino acids such as alanine, serine, leucine, isoleucine, threonine, glycine, proline, hydroxyproline, aspartic acid, arginine, and theanine and derivatives thereof; ethylene glycol, propylene glycol, 1,3-butylene glycol, glycerin, Polyhydric alcohols such as diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol, diglycerin, polyethylene glycol; ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monopropyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether , Diethylene glycol monopropyl ether, diethylene glycol Glycol ethers such as nobutyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, dipropylene glycol monoethyl ether, dipropylene glycol monopropyl ether; sugar alcohols such as mannitol, sorbitol, erythritol, xylitol, trehalose; lecithin, hydrogen Phospholipids such as added lecithin; Mucopolysaccharides such as sodium hyaluronate, sodium acetyl hyaluronate, heparin-like substances, chondroitin sulfate sodium; polymer compounds such as collagen, elastin, keratin, chitin, chitosan, gelatin, polyglutamic acid; sodium lactate N, such as sodium pyrrolidonecarboxylate
MF-derived ingredients: chamomile extract, aloe extract, aloe vera extract, chammellus extract,
In addition to plant extract extracts such as rosemary extract, thyme extract, tea extract, perilla extract, and the like. Preferably, glycine, glycerin, 1,3-butylene glycol,
Dipropylene glycol, diglycerin, diethylene glycol monoethyl ether, sodium hyaluronate, sodium acetyl hyaluronate, sodium pyrrolidone carboxylate, and polyglutamic acid.
保湿剤を用いる場合、本発明の効果を奏すれば特に制限されず、皮膚への使用感や効果
を考慮して適宜選択して用いることができるが、皮膚外用剤全体に対して、通常0.0001〜
50重量%、好ましくは0.1〜10重量%、より好ましくは0.5〜5重量%を挙げることができる。
When a moisturizer is used, it is not particularly limited as long as the effects of the present invention are exhibited, and can be appropriately selected and used in consideration of the feeling of use and effects on the skin. ~
50% by weight, preferably 0.1 to 10% by weight, more preferably 0.5 to 5% by weight.
美白剤としては、ハイドロキノン、アルブチンなどのキノン類、グリコール酸、クエン
酸、リンゴ酸、酒石酸、乳酸などのα−ヒドロキシ酸、アスコルビン酸、テトライソパル
ミチン酸アスコルビル、ステアリン酸アスコルビル、パルミチン酸アスコルビル、リン酸
L−アスコルビルマグネシウム、アスコルビン酸グルコシドなどのビタミンC又はその誘
導体、イリス(アイリス)、アーモンド、アロエ、イチョウ、ウーロン茶、エイジツ、オ
ウゴン、オウレン、オトギリソウ、オドリコソウ、海藻、カッコン、カミツレ、カンゾウ
、クチナシ、クジン、コムギ、コメ、コメハイガ、コメヌカ、シソ、シャクヤク、センキ
ュウ、ソウハクヒ、ダイズ、茶、テルミナリア、トウキ、トウキンセンカ、ハマメリス、
ベニバナ、ボタンピ、ヨクイニン、トウキ、エノキ、カキ(Diospyros kak
i)、チョウジ等の植物に由来する成分、エキス及び精油、プラセンタ、システイン、エ
ラグ酸、コウジ酸、フィチン酸、ルシノール、オリザノール等が挙げられる。好ましくは
、ハイドロキノン、アルブチン、乳酸、アスコルビン酸、テトライソパルミチン酸アスコ
ルビル、イリスエキス、テルミナリアエキス、システインを挙げることができる。これら
の美白剤は1種または2種以上を用いてもよい。
Whitening agents include hydroquinone, quinones such as arbutin, α-hydroxy acids such as glycolic acid, citric acid, malic acid, tartaric acid, and lactic acid, ascorbic acid, ascorbyl tetraisopalmitate, ascorbyl stearate, ascorbyl palmitate, phosphorus Vitamin C or derivatives thereof such as acid L-ascorbyl magnesium and ascorbic acid glucoside, Iris (iris), almond, aloe, ginkgo, oolong tea, ages, ogon, oulen, hypericum, licorice, seaweed, cuckoo, chamomile, licorice, gardenia, Kujin, wheat, rice, rice haiga, rice bran, perilla, peony, senkyu, sakuhakuhi, soybeans, tea, terminaria, touki, shinkinka, hamamelis,
Safflower, Buttonpi, Yokuinin, Toki, Enoki, Oyster (Diospyros kak)
i), components derived from plants such as clove, extract and essential oil, placenta, cysteine, ellagic acid, kojic acid, phytic acid, lucinol, oryzanol and the like. Preferred examples include hydroquinone, arbutin, lactic acid, ascorbic acid, ascorbyl tetraisopalmitate, Iris extract, terminaria extract, and cysteine. These whitening agents may be used alone or in combination of two or more.
上記美白剤を用いる場合、本発明の皮膚外用剤に配合する割合は、本発明の効果を奏す
れば特に制限されず、皮膚への使用感や効果を考慮して適宜選択して用いることができる
が、皮膚外用剤全体に対して、通常0.0003〜20重量%であり、好ましくは0.01〜10重量%
、特に好ましくは0.05〜5重量%であれば良い。
When using the above-mentioned whitening agent, the ratio to be blended in the external preparation for skin of the present invention is not particularly limited as long as the effects of the present invention are exhibited, and may be appropriately selected and used in consideration of use feeling and effects on the skin. However, it is usually 0.0003 to 20% by weight, preferably 0.01 to 10% by weight, based on the whole external preparation for skin.
Particularly preferably, it may be 0.05 to 5% by weight.
細胞賦活剤としては、γ-アミノ酪酸、ε-アミノカプロン酸などのアミノ酸類、γ−オ
リザノール、ジベンゾイルチアミン、ジベンゾイルチアミン塩酸塩、チアミン塩酸塩、チ
アミンセチル塩酸塩、チアミンチオシアン酸塩、チアミンラウリル塩酸塩、チアミン硝酸
塩、チアミンモノリン酸塩、チアミンリジン塩、チアミントリリン酸塩、チアミンモノリ
ン酸エステルリン酸塩、チアミンモノリン酸エステル、チアミンジリン酸エステル、チア
ミンジリン酸エステル塩酸塩、チアミントリリン酸エステル、チアミントリリン酸エステ
ルモノリン酸塩等のビタミンB1類、リボフラビン、フラビンモノヌクレオチド、フラビ
ンアデニンジヌクレオチド、リボフラビン酪酸エステル、リボフラビンテトラ酪酸エステ
ル、リボフラビン5’−リン酸エステルナトリウム、リボフラビンテトラニコチン酸エス
テル等のビタミンB2類、塩酸ピリドキシン、酢酸ピリドキシン、塩酸ピリドキサール、
5’−リン酸ピリドキサール、塩酸ピリドキサミン等のビタミンB6類パントテン酸、パ
ントテン酸カルシウム、パントテニルアルコール(パンテノール)、D−パンテサイン、
D−パンテチン、補酵素A、パントテニルエチルエーテル等のパントテン酸類などのビタ
ミン類などが挙げられる。好ましくは、γ-アミノ酪酸、ε-アミノカプロン酸などのアミ
ノ酸類、パントテン酸類などのビタミン類である。
Cell activators include amino acids such as γ-aminobutyric acid and ε-aminocaproic acid, γ-oryzanol, dibenzoylthiamine, dibenzoylthiamine hydrochloride, thiamine hydrochloride, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl Hydrochloride, thiamine nitrate, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate, thiamine monophosphate phosphate, thiamine monophosphate, thiamine diphosphate, thiamine diphosphate hydrochloride, thiamine triphosphate, Vitamin B1 such as thiamine triphosphate monophosphate, riboflavin, flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate, riboflavin tetrabutyrate, riboflavin 5'-phosphate Sodium Le, vitamin B2 such as riboflavin tetra nicotinate, pyridoxine hydrochloride, acetic pyridoxine, hydrochloride pyridoxal,
Vitamin B6 pantothenic acid such as 5′-phosphate pyridoxal phosphate, pyridoxamine hydrochloride, pantothenic acid calcium, pantothenyl alcohol (panthenol), D-pantesign,
Vitamins such as pantothenic acids such as D-pantethine, coenzyme A, pantothenyl ethyl ether and the like can be mentioned. Preferred are amino acids such as γ-aminobutyric acid and ε-aminocaproic acid, and vitamins such as pantothenic acids.
上記細胞賦活剤を用いる場合、本発明の効果を奏すれば特に制限されず、皮膚への使用
感や効果を考慮して適宜選択して用いることができるが、皮膚外用剤全体に対して、通常
0.0003〜10重量%であり、より好ましくは0.01〜5重量%である。
When using the above-mentioned cell activator, it is not particularly limited as long as the effects of the present invention are achieved, and can be appropriately selected and used in consideration of the feeling of use and effects on the skin, but for the entire skin external preparation, Normal
It is 0.0003-10 weight%, More preferably, it is 0.01-5 weight%.
抗シワ剤としては、コエンザイムQ10、カイネチン、グリコール酸、コラーゲン、ヒア
ルロン酸ナトリウム、アセチルヒアルロン酸ナトリウム、アロエエキス、海藻エキス、マ
ロニエエキス、ローズマリーエキス、ヤグルマソウエキスなどが挙げられ、好ましくはコ
エンザイムQ10、カイネチン、ヒアルロン酸ナトリウム、アセチルヒアルロン酸ナトリウ
ム、ローズマリーエキスである。
Examples of the anti-wrinkle agent include coenzyme Q10, kinetin, glycolic acid, collagen, sodium hyaluronate, sodium acetyl hyaluronate, aloe extract, seaweed extract, maroonier extract, rosemary extract, cornflower extract, preferably coenzyme Q10, It is kinetin, sodium hyaluronate, sodium acetyl hyaluronate, rosemary extract.
本発明で用いる抗シワ剤の配合量は、特に制限されないが、皮膚への使用感や効果を考
慮して適宜選択して用いることができる。皮膚外用剤全体として、通常0.0001〜30重量%
、好ましくは0.001〜25重量%、更に好ましくは0.01〜20重量%、特に好ましくは1〜20重量%であれば良い。
The compounding amount of the anti-wrinkle agent used in the present invention is not particularly limited, but can be appropriately selected and used in consideration of the feeling of use and effects on the skin. As a whole, the external preparation for skin is usually 0.0001-30% by weight
The content may be 0.001 to 25% by weight, more preferably 0.01 to 20% by weight, and particularly preferably 1 to 20% by weight.
本発明の皮膚外用剤の調製方法は、特に制限されず、通常の皮膚外用剤を調製するのに
必要な各種成分などを適宜選択、配合して、常法により調製することができる。また、本
発明の皮膚外用剤の外皮への適用量や用法は特に制限されず、通常、一日数回、適量を皮
膚等の外皮に塗布するなどして用いることができる。
The method for preparing the external preparation for skin of the present invention is not particularly limited, and can be prepared by a conventional method by appropriately selecting and blending various components necessary for preparing an ordinary external preparation for skin. Moreover, the application amount and usage of the external preparation for skin of the present invention to the outer skin are not particularly limited, and it can be used usually by applying an appropriate amount to the outer skin such as skin several times a day.
本発明の皮膚外用剤は、種々の形態に調製することができる。例えば、軟膏剤、液剤(
油状、ローション状、乳液状、エアゾール状を含む)、ゲル剤(液晶、マイクロエマルジ
ョン、リポソームを含む)、クリーム剤などの剤型が挙げられ、特に軟膏剤、ゲル剤(液
晶、マイクロエマルジョン、リポソームを含む)、クリーム剤に適用すると有用である。
また、使用感(べたつき、のび、しっとり感など)の観点から、水中油型が好ましい。
The external preparation for skin of the present invention can be prepared in various forms. For example, ointments, liquids (
Examples include oils, lotions, emulsions, and aerosols, gels (including liquid crystals, microemulsions, and liposomes), creams, and ointments, gels (liquid crystals, microemulsions, and liposomes). It is useful when applied to creams.
In addition, an oil-in-water type is preferable from the viewpoint of feeling of use (stickiness, spread, moist feeling, etc.).
本発明の皮膚外用剤の用途としては、尿素を高濃度含有していることから、手指のあれ
、ひじ・ひざ・かかと・くるぶし等の角化症、老人の乾皮症、さめ肌を治療するための角
質軟化剤などの医薬品、手荒れ、肌荒れ、唇の荒れ、日焼け後のほてり、しわ・たるみ、
肌を整える、唇のきめを整える、皮膚・唇をすこやかに保つ、皮膚・唇にうるおいを与え
る、皮膚・唇を保護する、皮膚の乾燥・しもやけ・ひび・あかぎれ・かぶれ等の予防、美
白などに用いる医薬部外品、保湿、角質軟化などに用いる化粧品等が好適な用途として例
示できるが、特にこれらに制限されない。
As an application of the external preparation for skin of the present invention, it contains urea in a high concentration, so that it treats keratosis such as elbows, knees, heels and ankles, psoriasis of the elderly, and shark skin. Pharmaceuticals such as keratin softener, rough hands, rough skin, rough lips, hot flashes after sunburn, wrinkles and sagging,
Prepares the skin, smoothes the lips, keeps the skin and lips healthy, moisturizes the skin and lips, protects the skin and lips, prevents the skin from drying, wrinkles, cracks, scratches and rashes, whitening, etc. Non-pharmaceuticals used in the field, cosmetics used for moisturizing, keratin softening, etc. can be exemplified as suitable applications, but not particularly limited thereto.
本発明の皮膚外用剤は、保存安定性や粘度等の品質を損なわず、また本発明の効果を損
なわない量的及び質的範囲内で、必要に応じて医薬品、医薬部外品または化粧品分野にお
いて一般的に用いられる各種の成分、例えば基剤、界面活性剤、増粘剤、保存剤、pH調
整剤、安定化剤、刺激軽減剤、防腐剤、着色剤、分散剤、香料等を配合することができる
。なお、これらの成分は1種単独で、または2種以上を任意に組み合わせて配合すること
ができる。
The external preparation for skin of the present invention does not impair quality such as storage stability and viscosity, and within the quantitative and qualitative range that does not impair the effects of the present invention, as necessary, in the pharmaceutical, quasi-drug or cosmetic field. Ingredients commonly used in the formulation, such as bases, surfactants, thickeners, preservatives, pH adjusters, stabilizers, irritation reducers, preservatives, colorants, dispersants, fragrances, etc. can do. In addition, these components can be mix | blended individually by 1 type or in combination of 2 or more types.
基剤:流動パラフィン、ゲル化炭化水素、オゾケライト、セレシン、ワセリン、ハード
ファット、マイクロクリスタリンワックス等の炭化水素、ラウリン酸、ミリスチン酸、パ
ルミチン酸、ステアリン酸、ベヘニン酸、イソステアリン酸、オレイン酸、リノール酸等
の脂肪酸、トリ2−エチルヘキサン酸グリセリル(トリオクタノイン)等のトリ脂肪酸グ
リセリド、ラウリルアルコール、セタノール、ステアリルアルコール、オレイルアルコー
ル、イソステアリルアルコール、2−オクチルドデカノール、ベヘニルアルコール、2−
ヘキシルデカノール等の高級アルコール、高重合メチルポリシロキサン、ジメチルポリシ
ロキサン、ジメチルシロキサン・メチル(ポリオキシエチレン)シロキサン・メチル(ポ
リオキシプロピレン)シロキサン共重合体、ジメチルシロキサン・メチル(ポリオキシエ
チレン)シロキサン共重合体、ジメチルシロキサン・メチル(ポリオキシプロピレン)シ
ロキサン共重合体、ポリオキシエチレン・メチルポリシロキサン共重合体、ポリ(オキシ
エチレン・オキシプロピレン)・メチルポリシロキサン共重合体、ジメチルシロキサン・
メチルセチルオキシシロキサン共重合体、ジメチルシロキサン・メチルステアロキシシロ
キサン共重合体、アクリル酸アルキル共重合体メチルポリシロキサンエステル、架橋型メ
チルポリシロキサン、架橋型メチルフェニルポリシロキサン、架橋型ポリエーテル変性シ
リコーン、架橋型アルキルポリエーテル変性シリコーン、架橋型アルキル変性シリコーン
等の重合型シリコーン、エチレングリコールモノアセタート、エチレングリコールジアセ
タート、トリエチレングリコールジアセタート、ヘキシレングリコールジアセタート、及
び2-メチル-2-プロペン-1,1-ジオールジアセタート等のグリコールアセタート、トリエチ
レングリコールジバレラート、2,2,4-トリメチル-1,3-ペンタンジオールモノイソブチラ
ート、2,2,4-トリメチル-1,3-ペンタンジオールジイソブチラート等のグリコールエステ
ル、エチレングリコールジアクリラート、ジエチレングリコールジアクリラート、プロピ
レングリコールモノアクリラート、2,2-ジメチル-トリメチレングリコールジアクリラー
ト、及び1,3-ブチレングリコールジアクリラート等のグリコールアクリラート、エチレン
グリコールジニトラート、ジエチレングリコールジニトラート、トリエチレングリコール
ジニトラート、及びプロピレングリコールジニトラート等のグリコールジニトラート、2,
2′-[1,4-フェニレンジオキシ]ジエタノール、ジオキサン、ブチレングリコールアジピン
酸ポリエステルなど。好ましくは、流動パラフィン、ワセリン、セタノール、ステアリル
アルコール、ジメチルポリシロキサンである。
Base: Liquid paraffin, gelled hydrocarbon, ozokerite, ceresin, petrolatum, hard fat, microcrystalline wax and other hydrocarbons, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, isostearic acid, oleic acid, linol Fatty acids such as acids, trifatty acid glycerides such as glyceryl tri-2-ethylhexanoate (trioctanoin), lauryl alcohol, cetanol, stearyl alcohol, oleyl alcohol, isostearyl alcohol, 2-octyldodecanol, behenyl alcohol, 2-
Higher alcohols such as hexyldecanol, highly polymerized methylpolysiloxane, dimethylpolysiloxane, dimethylsiloxane / methyl (polyoxyethylene) siloxane / methyl (polyoxypropylene) siloxane copolymer, dimethylsiloxane / methyl (polyoxyethylene) siloxane copolymer Polymer, dimethylsiloxane / methyl (polyoxypropylene) siloxane copolymer, polyoxyethylene / methylpolysiloxane copolymer, poly (oxyethylene / oxypropylene) / methylpolysiloxane copolymer, dimethylsiloxane /
Methylcetyloxysiloxane copolymer, dimethylsiloxane / methylstearoxysiloxane copolymer, alkyl acrylate copolymer methylpolysiloxane ester, crosslinked methylpolysiloxane, crosslinked methylphenylpolysiloxane, crosslinked polyether-modified silicone, Crosslinked alkyl polyether-modified silicones, polymerized silicones such as crosslinked alkyl-modified silicones, ethylene glycol monoacetate, ethylene glycol diacetate, triethylene glycol diacetate, hexylene glycol diacetate, and 2-methyl- Glycol acetate such as 2-propene-1,1-diol diacetate, triethylene glycol divalerate, 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate, 2,2,4- Trimethyl-1,3-pentane Glycol esters such as diisobutyrate, ethylene glycol diacrylate, diethylene glycol diacrylate, propylene glycol monoacrylate, 2,2-dimethyl-trimethylene glycol diacrylate, and 1,3-butylene glycol diacrylate Glycol dinitrates such as glycol acrylate, ethylene glycol dinitrate, diethylene glycol dinitrate, triethylene glycol dinitrate, and propylene glycol dinitrate,
2 '-[1,4-phenylenedioxy] diethanol, dioxane, butylene glycol adipic acid polyester, etc. Liquid paraffin, petrolatum, cetanol, stearyl alcohol, and dimethylpolysiloxane are preferred.
界面活性剤:ソルビタンモノイソステアレート、ソルビタンモノラウレート、ソルビタ
ンモノパルミテート、ソルビタンモノステアレート、ペンタ−2−エチルヘキシル酸ジグ
リセロールソルビタン、テトラ−2−エチルヘキシル酸ジグリセロールソルビタン等のソ
ルビタン脂肪酸エステル類、モノステアリン酸グリセリル、モノステアリン酸グリセリン
リンゴ酸等のグリセリン脂肪酸類、モノイソステアリン酸ポリグリセリル、ジイソステア
リン酸ポリグリセリル等のポリグリセリン脂肪酸類、モノステアリン酸プロピレングリコ
ール等のプロピレングリコール脂肪酸エステル類、ポリオキシエチレン硬化ヒマシ油40、
ポリオキシエチレン硬化ヒマシ油50、ポリオキシエチレン硬化ヒマシ油60、ポリオキシエ
チレン硬化ヒマシ油80などの硬化ヒマシ油誘導体、モノラウリル酸ポリオキシエチレン(2
0)ソルビタン(ポリソルベート20)、モノステアリン酸ポリオキシエチレン(20)ソルビタ
ン(ポリソルベート60)、モノオレイン酸ポリオキシエチレン(20)ソルビタン(ポリソルベ
ート80)などのポリオキシエチレンソルビタン脂肪酸エステル類、ポリオキシエチレンモ
ノヤシ油脂肪酸グリセリル、グリセリンアルキルエーテル、アルキルグルコシド、ポリオ
キシエチレンセチルエーテル、ステアリルアミン、オレイルアミンなど。好ましくは、ソ
ルビタンモノステアレート、ポリオキシエチレン硬化ヒマシ油50、ポリオキシエチレン硬
化ヒマシ油60、ポリソルベート60である。
Surfactants: Sorbitan fatty acid esters such as sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, diglycerol sorbitan penta-2-ethylhexylate, diglycerol sorbitan tetra-2-ethylhexylate Glyceryl fatty acids such as glyceryl monostearate and glyceryl monostearate malic acid, polyglyceryl fatty acids such as polyglyceryl monoisostearate and polyglyceryl diisostearate, propylene glycol fatty acid esters such as propylene glycol monostearate, polyoxyethylene cured Castor oil 40,
Hardened castor oil derivatives such as polyoxyethylene hardened castor oil 50, polyoxyethylene hardened castor oil 60, polyoxyethylene hardened castor oil 80, polyoxyethylene monolaurate (2
Polyoxyethylene sorbitan fatty acid esters such as 0) sorbitan (polysorbate 20), polyoxyethylene monostearate (20) sorbitan (polysorbate 60), polyoxyethylene monooleate (20) sorbitan (polysorbate 80), polyoxyethylene Mono coconut oil fatty acid glyceryl, glycerin alkyl ether, alkyl glucoside, polyoxyethylene cetyl ether, stearylamine, oleylamine and the like. Preferred are sorbitan monostearate, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, and polysorbate 60.
増粘剤:グアーガム、ローカストビーンガム、カラギーナン、キサンタンガム、デキス
トラン、メチルセルロース、エチルセルロース、カルボキシメチルセルロース、ヒドロキ
シエチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒ
ドロキシプロピルメチルセルロース、アルギン酸ナトリウム、アルギン酸プロピレングリ
コールエステル、ポリビニルアルコール、ポリビニルピロリドン、ポリビニルメチルエー
テル、カルボキシビニルポリマー、アクリル酸メタクリル酸アルキル共重合体、ポリアク
リル酸ナトリウム、ポリエチレングリコール、ベントナイト、デキストリン脂肪酸エステ
ル、ペクチンなど。好ましくは、ポリビニルアルコール、ポリビニルピロリドン、カルボ
キシビニルポリマー、アクリル酸メタクリル酸アルキル共重合体である。
Thickener: Guar gum, locust bean gum, carrageenan, xanthan gum, dextran, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium alginate, propylene glycol alginate, polyvinyl alcohol, polyvinylpyrrolidone , Polyvinyl methyl ether, carboxyvinyl polymer, alkyl methacrylate copolymer, sodium polyacrylate, polyethylene glycol, bentonite, dextrin fatty acid ester, pectin and the like. Preferred are polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, and alkyl methacrylate methacrylate copolymer.
保存剤:安息香酸、安息香酸ナトリウム、デヒドロ酢酸、デヒドロ酢酸ナトリウム、パ
ラオキシ安息香酸イソブチル、パラオキシ安息香酸イソプロピル、パラオキシ安息香酸ブ
チル、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸ベ
ンジル、パラオキシ安息香酸メチル、フェノキシエタノール、1,2−ヘキサンジオール
など。
Preservatives: Benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, benzyl paraoxybenzoate, paraoxybenzoic acid Methyl, phenoxyethanol, 1,2-hexanediol and the like.
pH調整剤:無機酸(塩酸、硫酸、リン酸、ポリリン酸、ホウ酸など)、有機酸(乳酸
、酢酸、クエン酸、酒石酸、リンゴ酸、コハク酸、コハク酸ナトリウム、シュウ酸、グル
コン酸、フマル酸、プロピオン酸、酢酸、アスパラギン酸、イプシロン−アミノカプロン
酸、グルタミン酸、アミノエチルスルホン酸など)、グルコノラクトン、酢酸アンモニウ
ム、無機塩基(炭酸水素ナトリウム、炭酸ナトリウム、水酸化カリウム、水酸化ナトリウ
ム、水酸化カルシウム、水酸化マグネシウムなど)、有機塩基(モノエタノールアミン、
トリエタノールアミン、ジイソプロパノールアミン、トリイソプロパノールアミン、リジ
ンなど)など。
pH adjusters: inorganic acids (hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, boric acid, etc.), organic acids (lactic acid, acetic acid, citric acid, tartaric acid, malic acid, succinic acid, sodium succinate, oxalic acid, gluconic acid, Fumaric acid, propionic acid, acetic acid, aspartic acid, epsilon-aminocaproic acid, glutamic acid, aminoethylsulfonic acid, etc.), gluconolactone, ammonium acetate, inorganic base (sodium bicarbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, Calcium hydroxide, magnesium hydroxide, etc.), organic bases (monoethanolamine,
Triethanolamine, diisopropanolamine, triisopropanolamine, lysine, etc.).
これらの成分は1種または2種以上を組み合わせて用いることができる。またそれらの
配合量は、本発明の効果を奏すれば特に制限されないが、望ましくは薬事法上許容される
上限配合量を限度に適宜選択使用することができる。具体的には、皮膚外用剤100重量部
あたり通常0.001〜20重量部、好ましくは0.001〜10重量部、より好ましくは0.001〜5重量
部の範囲から目的に応じて調製することができる。
These components can be used alone or in combination of two or more. Moreover, those compounding amounts are not particularly limited as long as the effects of the present invention are obtained, but can be suitably selected and used as long as the upper limit compounding amount allowed by the Pharmaceutical Affairs Law is desirable. Specifically, it can be prepared according to the purpose from the range of usually 0.001 to 20 parts by weight, preferably 0.001 to 10 parts by weight, more preferably 0.001 to 5 parts by weight per 100 parts by weight of the external preparation for skin.
さらに本発明は、尿素析出抑制方法をも包含する。本発明の方法において、尿素析出抑
制は、尿素およびレチノールまたはその誘導体を共存させることによって達成できる。さ
らにトコフェロールまたはその誘導体を共存させるとより好ましい。
本発明の方法において、尿素、レチノールまたはその誘導体、およびトコフェロールま
たはその誘導体は、前記皮膚外用剤で用いたものと同様である。尿素、レチノールまたは
その誘導体、トコフェロールまたはその誘導体の配合量は、本発明の効果を奏すれば特に
制限されないが、尿素は通常1〜30重量%、好ましくは3〜25重量%、さらに好ましくは5
〜25重量%、特に好ましくは10〜20重量%であり、レチノールまたはその誘導体は通常0.
001〜1重量%、好ましくは0.01〜0.5重量%であり、トコフェロールまたはその誘導体は
通常0.001〜5重量%、好ましくは0.01〜3重量%、特に好ましくは0.5〜2重量%である。
Furthermore, the present invention includes a method for suppressing urea precipitation. In the method of the present invention, urea precipitation suppression can be achieved by coexisting urea and retinol or a derivative thereof. Further, it is more preferable that tocopherol or a derivative thereof coexists.
In the method of the present invention, urea, retinol or a derivative thereof, and tocopherol or a derivative thereof are the same as those used in the external preparation for skin. The blending amount of urea, retinol or a derivative thereof, tocopherol or a derivative thereof is not particularly limited as long as the effect of the present invention is achieved, but urea is usually 1 to 30% by weight, preferably 3 to 25% by weight, more preferably 5
-25% by weight, particularly preferably 10-20% by weight, with retinol or its derivatives usually being 0.
It is 001 to 1% by weight, preferably 0.01 to 0.5% by weight, and tocopherol or a derivative thereof is usually 0.001 to 5% by weight, preferably 0.01 to 3% by weight, particularly preferably 0.5 to 2% by weight.
さらに本発明は、レチノール又はその誘導体の安定化方法をも包含する。本発明の方法において、レチノール又はその誘導体の安定化は、尿素およびレチノールまたはその誘導体を共存させることによって達成できる。さらにトコフェロールまたはその誘導体を共存させるとより好ましい。
本発明の方法において、尿素、レチノールまたはその誘導体、およびトコフェロールまたはその誘導体は、前記皮膚外用剤で用いたものと同様である。尿素、レチノールまたはその誘導体、トコフェロールまたはその誘導体の配合量は、本発明の効果を奏すれば特に制限されないが、尿素は通常1〜30重量%、好ましくは3〜25重量%、さらに好ましくは5〜25重量%、特に好ましくは10〜20重量%であり、レチノールまたはその誘導体は通常0.001〜1重量%、好ましくは0.01〜0.5重量%であり、トコフェロールまたはその誘導体は通常0.001〜5重量%、好ましくは0.01〜3重量%、特に好ましくは0.5〜2重量%である。
Furthermore, this invention also includes the stabilization method of retinol or its derivative (s). In the method of the present invention, stabilization of retinol or a derivative thereof can be achieved by coexisting urea and retinol or a derivative thereof. Further, it is more preferable that tocopherol or a derivative thereof coexists.
In the method of the present invention, urea, retinol or a derivative thereof, and tocopherol or a derivative thereof are the same as those used in the external preparation for skin. The blending amount of urea, retinol or a derivative thereof, tocopherol or a derivative thereof is not particularly limited as long as the effect of the present invention is achieved, but urea is usually 1 to 30% by weight, preferably 3 to 25% by weight, more preferably 5 -25% by weight, particularly preferably 10-20% by weight, retinol or a derivative thereof is usually 0.001-1% by weight, preferably 0.01-0.5% by weight, tocopherol or a derivative thereof is usually 0.001-5% by weight, Preferably it is 0.01 to 3 weight%, Most preferably, it is 0.5 to 2 weight%.
以下に実施例を挙げて本発明を具体的に説明するが、これらの実施例は何ら本発明の範
囲を限定するものではない。なお、配合量は特に単位の記載のないものについては、すべ
て重量%を表す。
EXAMPLES The present invention will be specifically described below with reference to examples, but these examples do not limit the scope of the present invention. In addition, especially a compounding quantity does not have a unit description, all represent weight%.
試験例1 使用感試験
表1に示す処方に従い、精製水と尿素を合わせて70℃に加温溶解した水相に、その他の
全成分を70℃で加温溶解した油相を攪拌しながら混合し、室温まで冷却して調製した各製
剤(クリーム剤)について、30代女性5名に製剤塗布時の使用感を下記基準に基づいて
評価してもらい、その平均点から以下のように判定した。
評価基準 5点:皮膚表面がざらつかず、しっとりと潤う感触、4点:皮膚表面がざら
つかず、さらっとした感触、3点:皮膚表面はざらつかないが、特に感触に変化が感じら
れない、2点:皮膚表面がややざらつく感触、1点:皮膚表面がざらつく感触
判定基準 ◎:4.5以上、○:3.5〜4.4、△:2.5〜3.4、×:2.4以下
結果を表1に示す。
Test example 1 Usability test
In accordance with the formulation shown in Table 1, the purified water and urea are combined and dissolved in water at 70 ° C, and the oil phase in which all other components are heated and dissolved at 70 ° C is mixed with stirring and cooled to room temperature. Each of the preparations (cream preparations) prepared was evaluated by 5 females in their 30s based on the following criteria for use feeling when applying the preparations, and the average score was determined as follows.
Evaluation criteria 5 points: Feeling that the skin surface is not rough and moisturizing, 4 points: Feeling that the skin surface is not rough and dry, 3 points: Although the skin surface is not rough, especially changes in feel are felt None, 2 points: Feel that the skin surface is slightly rough, 1 point: Feel that the skin surface is rough Judgment criteria A: 4.5 or more, ○: 3.5 to 4.4, Δ: 2.5 to 3.4, ×: 2.4 or less The results are shown in Table 1.
比較例1は尿素が10%であるため比較例2よりもざらつき度合いは低かったが、実施例
1〜3において大幅な改善が見られた。一方、比較例2では全員が「ざらつく」と答えた
が、実施例4ではざらつきはかなり低減され、酢酸トコフェロールを入れた実施例5,6
では、さらに使用感は改善した。
このように、本発明は使用感に優れた皮膚外用剤であり、尿素などの析出を抑制してい
ることなどから、有効成分の薬理効果を十分に期待することができ、特に有用である。
In Comparative Example 1, since the amount of urea was 10%, the degree of roughness was lower than that in Comparative Example 2, but significant improvements were observed in Examples 1 to 3. On the other hand, in Comparative Example 2, all responded “Roughness”, but in Example 4, the roughness was considerably reduced and Examples 5 and 6 were added tocopherol acetate.
Then, the usability improved further.
As described above, the present invention is an external preparation for skin having an excellent usability and is particularly useful because it can sufficiently expect the pharmacological effect of the active ingredient because it suppresses precipitation of urea and the like.
試験例2 保湿性試験
温度23±2℃、湿度55±15%に設定した環境下で、Hos:HR-1系雄性ヘアレスマウス(4
週齡、1群8匹)の背部皮膚表面の電気伝導度(μs)を、表角層水分量測定装置(SKICO
N-200EX、アイ・ビー・エス株式会社製)により測定した(正常値)。
次に、アセトン:エーテル=1:1混合液を含ませた脱脂綿を60秒保持し、5秒後に蒸
留水を含ませた脱脂綿を60秒保持する処理を行った。この処理を5時間以上の間隔を空け
て2日間で3回実施し、肌荒れを人工的に誘発した乾燥肌マウスを作製した。この乾燥肌マウスに、表2に記載の各皮膚外用剤(表1と同様に調製:クリーム状)を1回当たり50μL、試験開始時(0時間)、約3時間後、約6時間後、約24時間後、約27時間後、及び約30時間後に塗布した。皮膚外用剤塗布前(初期値)、並びに試験開始24時間後及び48時間後に、マウスの乾燥肌上の電気伝導度を測定した。なお、試験開始24時間後の電気伝導度の測定は、試験開始24時間後の皮膚外用剤の塗布前に実施した。また、比較例6として無塗布群も同様に電気伝導度の測定を実施した。
結果を表2に示す。
Test Example 2 Moisturizing test
In an environment set at a temperature of 23 ± 2 ° C and a humidity of 55 ± 15%, Hos: HR-1 male hairless mice (4
The electrical conductivity (μs) of the dorsal skin surface of the weekly skin, 8 per group)
N-200EX, manufactured by IBS Co., Ltd.) (normal value).
Next, the absorbent cotton containing the acetone: ether = 1: 1 mixed solution was held for 60 seconds, and after 5 seconds, the absorbent cotton containing distilled water was held for 60 seconds. This treatment was carried out 3 times in 2 days with an interval of 5 hours or more to produce dry skin mice in which rough skin was artificially induced. To this dry skin mouse, each external preparation for skin described in Table 2 (prepared in the same manner as in Table 1: cream), 50 μL per time, at the start of the test (0 hour), after about 3 hours, after about 6 hours, The coating was applied after about 24 hours, about 27 hours, and about 30 hours. The electrical conductivity on the dry skin of the mice was measured before applying the skin external preparation (initial value), and 24 hours and 48 hours after the start of the test. In addition, the measurement of the electrical conductivity 24 hours after the start of the test was performed before the application of the skin external preparation 24 hours after the start of the test. Moreover, the electrical conductivity was similarly measured for the non-coated group as Comparative Example 6.
The results are shown in Table 2.
尿素の保湿作用は持続性がなく、比較例3は24、48時間後において比較例5と同程度の
効果であること、比較例4、5からレチノール誘導体を加えただけではさほど水分含量は
上昇しないことが確認された。一方、実施例6は比較例3、4よりもはるかに高い角質水
分含量を保持していることがわかった。
また、表2の処方から酢酸トコフェロールを除いた製剤についても表2と同様の効果が
見られたが、酢酸トコフェロールを含有している表2のほうが全体として角質水分含量の
値が高く、表2の実施例6がもっとも高い角質水分含量を示した。
The moisturizing action of urea is not persistent, and Comparative Example 3 has the same effect as Comparative Example 5 after 24 and 48 hours, and the water content is increased only by adding a retinol derivative from Comparative Examples 4 and 5. It was confirmed not to. On the other hand, Example 6 was found to retain a much higher keratin water content than Comparative Examples 3 and 4.
Moreover, the same effect as Table 2 was seen also about the formulation which remove | excluded tocopherol acetate from the prescription of Table 2, However, Table 2 containing tocopherol acetate has a higher value of keratin water content as a whole. Example 6 showed the highest keratin water content.
試験例3 安定性試験
表1、2記載の実施例3、6および比較例4について、40℃で6カ月保存した後、以
下の(1)及び(2)の方法によって実施例の尿素の安定性を評価した。また、パルミチ
ン酸レチノールの残存量を日本薬局方に準じて測定した。
(1)各実施例を0.5gとり、ガラス平板上で薄く均一に塗り広げて尿素の析出を目視
にて確認した。
(2)各実施例を1.0gとり、アンモニア臭の有無を官能にて評価した。
いずれの実施例も尿素の析出、アンモニア臭が観察されず、尿素が安定に保持されてい
ることが確認された。
また、パルミチン酸レチノールの残存量は、実施例3では87.5%、実施例6では88.2%
、比較例4では78.8%であり、本発明の実施例では比較例よりもレチノール誘導体の残存
量が約10%も向上した。
Test Example 3 Stability test
For Examples 3 and 6 and Comparative Example 4 listed in Tables 1 and 2, after storage at 40 ° C. for 6 months, the stability of urea of the examples was evaluated by the following methods (1) and (2). Moreover, the residual amount of retinol palmitate was measured according to the Japanese Pharmacopoeia.
(1) 0.5 g of each Example was taken and spread thinly and uniformly on a flat glass plate, and precipitation of urea was visually confirmed.
(2) 1.0 g of each Example was taken and the presence or absence of ammonia odor was evaluated by sensory evaluation.
In any of the examples, precipitation of urea and ammonia odor were not observed, and it was confirmed that urea was stably maintained.
The residual amount of retinol palmitate was 87.5% in Example 3 and 88.2% in Example 6.
In Comparative Example 4, it was 78.8%, and in the examples of the present invention, the residual amount of the retinol derivative was improved by about 10% compared to the comparative example.
試験例4 刺激性試験
表1記載の実施例1〜6について、刺激性の有無を評価するため、各々3名のモニター
の上腕部に製剤0.5g塗布し、塗布後の皮膚の状態(赤みが出ていないか)と、刺激感
(ピリピリしたり、かゆみや灼熱感を感じる)がないか評価を行った。
その結果、すべての実施例において、3名のすべてのモニターが刺激を感じることがな
く、本発明の実施例は刺激がなく安全な皮膚外用剤であることが確認された。
Test Example 4 Irritation test
About Examples 1-6 of Table 1, in order to evaluate the presence or absence of irritation, 0.5 g of the preparation was applied to the upper arm of each of the three monitors, and the skin condition after application (whether redness was present) And evaluated whether there was a feeling of irritation (feeling tingling, itching and burning).
As a result, in all the examples, all three monitors did not feel irritation, and it was confirmed that the examples of the present invention are safe and have no irritation.
試験例5 肌荒れ改善効果評価試験
表1記載の実施例6について、肌荒れ改善効果を評価した。具体的には手荒れのひどい患部を有する30代の女性10名に対して、4週間にわたって、当該患部と正常な皮膚状態の手の甲に、就寝前と乾燥が気になった時に適量を塗布させた。塗布開始1週間後、2週間後及び4週間後に、手荒れ患部と手の甲の電気伝導度(μs)を、表角層水分量測定装置(SKICON-200EX、アイ・ビー・エス株式会社製)により測定した。
塗布前の手荒れ患部と手の甲の電気伝導度をそれぞれ1として、塗布開始1週間後、2週間後及び4週間後の電気伝導度の相対値を算出した。
結果を表3に示す。
Test Example 5 Skin Roughness Improvement Effect Evaluation Test
About Example 6 of Table 1, the rough skin improvement effect was evaluated. Specifically, for 10 women in their 30s who had severely affected areas of rough hands, an appropriate amount was applied to the affected areas and back of the normal skin for 4 weeks when they were concerned about bedtime and dryness. . After 1 week, 2 weeks and 4 weeks after the start of application, the electrical conductivity (μs) of the affected area of the hand and the back of the hand was measured with a surface angle layer moisture measuring device (SKICON-200EX, manufactured by IBS Corp.). did.
Relative values of the electrical conductivity at 1 week, 2 weeks and 4 weeks after the start of application were calculated, assuming that the electrical conductivity of the rough hand affected area before application and the back of the hand were 1, respectively.
The results are shown in Table 3.
実施例6の塗布によって、手荒れのひどい患部の水分量が顕著に上昇した。また、10名全ての女性において、4週間後には、幹部の手あれが改善していた。また、手の甲についても、塗布前よりも水分量の増加が認められた。
以上の結果から、本発明には角質を正常化して、手あれを改善する効果に優れていることが明らかとなった。
The application of Example 6 markedly increased the water content in the affected area with severe hand roughness. Moreover, in all 10 women, management skills improved after 4 weeks. In addition, an increase in water content was also observed on the back of the hand compared to before application.
From the above results, it has been clarified that the present invention is excellent in the effect of normalizing keratin and improving touch.
以下に製剤実施例を挙げる。なお、以下の実施例中の配合量は、特に単位の記載のない
ものについてはすべて重量%を表す。
The formulation examples are given below. In addition, the compounding quantity in the following Examples represents weight% about all the things which have no description of a unit especially.
Claims (6)
(B)酢酸レチノール、パルミチン酸レチノールおよびδ-レチノイン酸トコフェロールからなる群から選択される1種または2種以上0.5重量%、および
(C)トコフェロール、または酢酸トコフェロール、ニコチン酸トコフェロール、リノレン酸トコフェロール、コハク酸トコフェロールから選択されるトコフェロールの誘導体、若しくはその塩を含有する皮膚外用剤。 (A) 10-20% by weight of urea,
(B) retinol acetate, 0.5 wt% of one or more members selected from the group consisting of retinol palmitate and δ- retinoic acid tocopherol, and (C) tocopherol or tocopherol acetate, tocopherol nicotinate, tocopherol linolenic acid, A skin external preparation containing a tocopherol derivative selected from tocopherol succinate or a salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007167688A JP5279209B2 (en) | 2006-06-27 | 2007-06-26 | Topical skin preparation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006177373 | 2006-06-27 | ||
JP2006177373 | 2006-06-27 | ||
JP2007167688A JP5279209B2 (en) | 2006-06-27 | 2007-06-26 | Topical skin preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008031159A JP2008031159A (en) | 2008-02-14 |
JP5279209B2 true JP5279209B2 (en) | 2013-09-04 |
Family
ID=39120965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007167688A Active JP5279209B2 (en) | 2006-06-27 | 2007-06-26 | Topical skin preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5279209B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5569918B2 (en) * | 2008-08-08 | 2014-08-13 | 株式会社 資生堂 | Topical skin preparation |
JP6222894B2 (en) * | 2012-03-30 | 2017-11-01 | 小林製薬株式会社 | Epidermis thickener |
KR102026800B1 (en) * | 2012-11-13 | 2019-09-30 | (주)아모레퍼시픽 | Skin external composition containing thioredoxin |
JP6542177B2 (en) * | 2016-10-11 | 2019-07-10 | 小林製薬株式会社 | Epidermis thickening promoter |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0717994A1 (en) * | 1994-07-07 | 1996-06-26 | Ignacio Anton Lujambio Galdeano | New formulation for the topical treatment of psoriasis |
JPH08259442A (en) * | 1995-03-17 | 1996-10-08 | Shiseido Co Ltd | Composition containing urea at high concentration and prevention of crystal deposition of urea |
DE19518845A1 (en) * | 1995-05-23 | 1996-11-28 | Beiersdorf Ag | Cosmetic or dermatological preparations containing phytic acid |
JPH092939A (en) * | 1995-06-19 | 1997-01-07 | Tsumura & Co | Bath medicine composition and its use |
CN1371273A (en) * | 1999-06-28 | 2002-09-25 | 宝洁公司 | Cosmetic composition containing quaternary ammonium compound and tocopherol |
JP2001131063A (en) * | 1999-10-29 | 2001-05-15 | Eisai Co Ltd | Method for inhibiting crystallization of urea in urea- formulated composition |
JP2002275454A (en) * | 2001-03-16 | 2002-09-25 | Daizo:Kk | Water-containing aerosol composition and method for stabilizing water-containing aerosol product |
JP2004035458A (en) * | 2002-07-03 | 2004-02-05 | Kanebo Ltd | Transparent liquid cosmetic |
WO2004060393A2 (en) * | 2002-12-30 | 2004-07-22 | Thorel Jean-Noel | Cutaneous metabolic bio-activator |
JP2005060386A (en) * | 2003-07-29 | 2005-03-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
JP2005060230A (en) * | 2003-08-08 | 2005-03-10 | Rohto Pharmaceut Co Ltd | Emulsified composition |
-
2007
- 2007-06-26 JP JP2007167688A patent/JP5279209B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008031159A (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI392515B (en) | Skin topical composition | |
JP5406531B2 (en) | Topical skin preparation | |
US20130210921A1 (en) | Method for Giving Warmth to Skin | |
JP4786630B2 (en) | Topical skin preparation | |
JP2005060234A (en) | External preparation for skin | |
JP5279209B2 (en) | Topical skin preparation | |
JP2013116870A (en) | Skin care composition | |
JP2003128531A (en) | Dermal external agent | |
JP4824337B2 (en) | Topical skin preparation | |
JP4824336B2 (en) | Topical skin preparation | |
JP2009269851A (en) | Inhibitor of prostaglandin e2 production and its utilization | |
JP2005060233A (en) | External preparation for skin | |
JP5338030B2 (en) | Adapalene-containing external preparation composition | |
JP4993890B2 (en) | Topical skin preparation | |
JP2004123575A (en) | Gel-like composition for external use | |
JP2007045808A (en) | Skin care preparation | |
JP2004075540A (en) | Gel-like composition for external preparations | |
JPH10279421A (en) | Preparation for external use for skin | |
JP2020015677A (en) | External composition containing cholesterol and/or phytosterol | |
JP5980171B2 (en) | Adapalene-containing external preparation composition | |
JP2019006696A (en) | Active oxygen scavenger | |
JP5734686B2 (en) | Skin external composition | |
JP6542177B2 (en) | Epidermis thickening promoter | |
JP2018002651A (en) | Chronic keratosis eczema improver | |
JP6038246B2 (en) | Erythema or edema improver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100527 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120404 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120723 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120821 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121211 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130430 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130521 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5279209 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |